Breaking News, Collaborations & Alliances

HTG, Sanofi US in Companion Diagnostic Pact

Aims to identify biomarkers for Sanofi compound

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

HTG Molecular Diagnostics has established a collaborative agreement with Sanofi US to identify biomarkers for the development of a molecular companion diagnostic test for a novel Sanofi investigational compound. HTG’s qNPA technology measures mRNA and/or miRNA expression in tumor samples, allowing clinicians to identify certain biomarkers relevant to patient selection and therapy. “We are pleased to be a partner with Sanofi in answering the need for personalized cancer treatments. qNPA offers o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters